Jagsonpal Pharmaceuticals Buyback 2026 Record Date, Price & Ratio Details

Jagsonpal Pharmaceuticals Buyback 2026 details: The Jagsonpal Pharmaceuticals Buyback open date is 2026. Jagsonpal Pharmaceuticals Buyback record date is 2026. The investor should buy the Jagsonpal Pharmaceuticals Buyback shares before the record date to get eligibility for the buyback.

Jagsonpal Pharmaceuticals Buyback 2026

Jagsonpal Pharmaceuticals’ buyback of ₹40.00 crores was approved by the board of directors at the meeting held on March 12, 2026. Jagsonpal Pharmaceuticals’ buyback will be done via the Tender Offer route through the stock exchange mechanism. The board of directors of the company approved the buyback by the Company of its fully paid-up equity shares having a face value of ₹10 each equity share at a price of ₹250 per Equity Share and for an aggregate amount not exceeding ₹40.00 crores from the shareholders. Check out Jagsonpal Pharmaceuticals Buyback 2026 details below:


Jagsonpal Pharmaceuticals Buyback About us

To be updated soon

Jagsonpal Pharmaceuticals Buyback History

  • N/A

Jagsonpal Pharmaceuticals Buyback 2026 Dates

Buyback Meeting Date:March 12, 2026
Buyback Announcement Date:March 12, 2026
Buyback Record Date:2026
Last Date to Buy Shares:2026
Buyback Open Date:2026
Buyback Close Date:2026
Finalization of Buyback Acceptance:2026

Jagsonpal Pharmaceuticals Buyback 2026 Offer Details

Jagsonpal Pharmaceuticals Buyback of 16,00,000 equity shares at a price of ₹250 per equity share. The buyback offers not to exceed ₹40.00 crores of the total buyback offer size.

Offer Amount:₹40.00 Crores
Number of Shares:16,00,000 Equity Shares
Face Value:₹10 per equity share
Buyback Price:₹250 per equity share
Listing:BSE, NSE
Buyback Type:Tender Offer
Letter of Offer:Click Here

Jagsonpal Pharmaceuticals Buyback 2026 Acceptance Ratio

The investor should buy around 800 shares at a current market price of ₹183.86 (as of date). The calculation will be ₹2,00,000 / ₹250 buyback price = 800 shares.

Acceptance RatioInvestmentShares BuybackProfit
33%₹1,47,200264₹48,576
50%₹1,47,200400₹73,600
75%₹1,47,200600₹1,10,400
100%₹1,47,200800₹1,47,200

Jagsonpal Pharmaceuticals Financial Report

₹ in Crores
YearRevenueExpensePAT
2023₹242.45₹204.18₹26.72
2024₹217.98₹188.11₹22.46
2025₹276.91₹226.73₹55.36

How to Participate in Jagsonpal Pharmaceuticals Buyback 2026

The investors are eligible for the buyback scheme who have Jagsonpal Pharmaceuticals Buyback shares in their Demat Account as the Record Date. Eligible Share Holders can participate in the Jagsonpal Pharmaceuticals Buyback 2026 scheme as per the opening form by selling their shares. The payment will be given as per the Jagsonpal Pharmaceuticals Buyback accepted shares by the company under the Jagsonpal Pharmaceuticals Buyback scheme.

Jagsonpal Pharmaceuticals Buyback 2026 Registrar

To be updated soon

Jagsonpal Pharmaceuticals Buyback 2026 Lead Managers

  • To be updated soon

Jagsonpal Pharmaceuticals Company Address

Jagsonpal Pharmaceuticals Ltd.
Plot No. 412-415,
Nimal Tower, 3rd Floor, Phase IV
Udyog Vihar Sector 18
Gurgaon, Haryana, 122015
Phone: 0124-4406710
Email: cs@jagsonpal.com
Website: https://www.jagsonpal.com/

Jagsonpal Pharmaceuticals Buyback 2026 FAQs


When is Jagsonpal Pharmaceuticals Buyback 2026 Record Date?

Jagsonpal Pharmaceuticals Buyback 2026 record date is 2026.

When is Jagsonpal Pharmaceuticals Buyback 2026 Open Date?

Jagsonpal Pharmaceuticals Buyback 2026 open date is 2026.

What is Jagsonpal Pharmaceuticals Buyback 2026 Price?

The company has fixed the price at ₹250 per share.

How to apply for Jagsonpal Pharmaceuticals Buyback 2026?

As per the record date you need to have Jagsonpal Pharmaceuticals Buyback shares in your Demat Account. You can participate in buyback after having the stock in your Account.

Table of Contents

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.

Disclaimer: This content is provided strictly for educational and informational purposes. The securities or investments mentioned are not to be considered as investment advice or recommendations. The Investors are advised to do their own research or connect with a financial advisor before making any investment decisions.

Leave a Reply

Your email address will not be published. Required fields are marked *